Related Experiment Videos
O6-benzylguanine and its role in chemotherapy
1Department of Medicine, Committees on Clinical Pharmacology and Cancer Biology, University of Chicago, Chicago, Illinois 60637, USA.
Abstract:
The presence of the DNA repair protein, O6-alkylguanine-DNA alkyltransferase (AGT) in tumor cells is a significant source of resistance to chemotherapeutic alkylnitrosoureas and alkyltriazenes. O6-Benzylguanine provides a means to effectively inactivate the AGT protein and increase the chemotherapeutic effectiveness of chloroethylating and methylating agents in vitro and in human tumor xenograft models. Phase I clinical trials of the combination of O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea are ongoing. Efforts directed at overcoming potential enhanced hematopoietic toxicity and mutagenicity have included the use of gene therapy to express an alkyltransferase gene in the relevant marrow stem cells. Altered AGT proteins resistant to O6-benzylguanine generated from point mutations in the mammalian alkyltransferase gene have been expressed in animal models using retroviral transduction techniques. It is anticipated that the successful application of this approach in humans may provide a means to increase the therapeutic index of O6-benzylguanine and 1, 3-bis(2-chloroethyl)-1-nitrosourea.
Insights
O6-Benzylguanine inactivates the DNA repair protein AGT, enhancing chemotherapy effectiveness against tumors. Gene therapy strategies are being explored to mitigate potential toxicities and improve treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Tumor resistance to chemotherapy often stems from the DNA repair protein O6-alkylguanine-DNA alkyltransferase (AGT).
- AGT inactivates critical chemotherapeutic agents like alkylnitrosoureas and alkyltriazenes.
- Overcoming AGT-mediated resistance is crucial for improving cancer treatment efficacy.
Purpose of the Study:
- To evaluate O6-Benzylguanine as a strategy to overcome AGT-mediated chemoresistance.
- To explore gene therapy approaches for managing potential toxicities associated with combined therapies.
- To investigate methods for enhancing the therapeutic index of chemotherapy agents.
Main Methods:
- In vitro and human tumor xenograft models were used to assess O6-Benzylguanine efficacy.
- Phase I clinical trials combined O6-benzylguanine with 1,3-bis(2-chloroethyl)-1-nitrosourea.
- Retroviral transduction techniques were employed to express altered AGT proteins in animal models.
Main Results:
- O6-Benzylguanine effectively inactivates AGT, increasing the potency of chloroethylating and methylating agents.
- Ongoing clinical trials are investigating the safety and efficacy of this combination therapy.
- Animal models demonstrated the expression of O6-benzylguanine-resistant AGT variants.
Conclusions:
- O6-Benzylguanine is a promising agent for overcoming AGT-mediated chemotherapy resistance.
- Gene therapy offers a potential strategy to manage enhanced toxicity and mutagenicity.
- Further research aims to optimize combination therapies for improved cancer treatment outcomes.